RFRicardo A. Franco

Ricardo A. Franco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ricardo A. Franco has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

    by Mark S. Sulkowski, Anthony Martinez, Gia L. Tyson, Kathleen Scholz, Ricardo A. Franco, Anita Kohli, Susan F. Julius, Paulina Deming, Scott A. Fink, Keisa Lynch, et al.

    All‐oral, direct‐acting antivirals can cure hepatitis C virus (HCV) in almost all infected individuals; yet, many individuals with chronic HCV are not treated, and the incidence of acute HCV is increasing in some countries, including the United States. Strains on healthcare resources during the COVID‐19 pandemic negatively impacted the progress toward the World Health Organization goal to eliminate HCV by 2030, especially among persons who inject drugs (PWID). Here, we present a holistic conceptual framework termed LOTUS (Leveraging Opportunities for Treatment/User Simplicity), designed to integrate the current HCV practice landscape and invigorate HCV treatment programs in the setting of endemic COVID‐19: (A) treatment as prevention (especially among PWID), (B) recognition that HCV cure may be achieved with variable adherence with evidence supporting some forgiveness for missed doses, (C) treatment of all persons with active HCV infection (viremic), regardless of acuity, (D) minimal monitoring (MinMon) during treatment, and (E) rapid test and treat (TnT). The objective of this article is to review the current literature supporting each LOTUS petal; identify remaining gaps in knowledge or data; define the remaining barriers facing healthcare providers; and review evidence‐based strategies for overcoming key barriers.


  • Open Access

    2496. Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden

    by Nicholas Forrister, Austin Nguyen, Ricardo A Franco, David Redden

    The advent of direct-acting antivirals (DAAs) calls for optimized hepatitis C virus (HCV) screening, linkage to care (LTC), access to cure, and mitigation of disease burden among health systems. We assessed HCV burden and care gaps among inpatients in a large volume, tertiary care setting during the DAA era. This is a retrospective cohort analysis of inpatients admitted at least once to medicine services from 2014 to 2021. We used analytic software to query electronic health records. We assessed demographics, comorbidities, HCV diagnosis, LTC, and treatment occurring at any point during the study period. Odds ratios (OR) were utilized to assess differences in key comparator groups. Baseline characteristics of inpatients admitted to medicine services from 2014 to 2021 and status of testing for Hepatitis C virus infection. Mean age is 62 with standard deviation of 17.8 years. *Diagnosis based on ICD-10 diagnosis codes in electronic medical records. In this large longitudinal analysis of inpatients cared for at a tertiary safety net hospital, a high proportion of individuals underwent HCV screening, and infection was highly prevalent. Care disparities remain and further optimization of HCV screening, LTC, and treatment will need to target younger populations, those with opioid use disorder, and living in rural areas. Ricardo A. Franco, MD, Abbvie: Grant/Research Support|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Merck: Grant/Research Support|Theratechnologies: Advisor/Consultant

  • A COVID-19 monitoring process for healthcare workers utilizing occupational health

    by J C Crosby, R A Lee, G McGwin, S L Heath, G A Burkholder, R M Gravett, E T Overton, G Locks, M E Fleece, R Franco, et al.

    Background: Hospital-based occupational health (HBOH) is uniquely positioned to not only prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, but to care for healthcare workers (HCWs) sick with coronavirus disease 2019 (COVID-19). Aims: The primary objective of this study is to describe a system where HBOH services were adapted to provide a monitoring programme whereby HCWs with SARS-CoV-2 received daily evaluations and treatment options in order to improve access to care, and to report the clinical outcomes and predictors of hospitalization in HCWs enrolled in the programme. A secondary objective is to compare clinical outcomes to data on national HCWs with COVID-19. Methods: This retrospective cohort study used survey data collected on HCWs at a university health system with COVID-19 from 1 March 2020 through 1 December 2021. A firth regression model was used to examine the unadjusted and adjusted association between clinical factors and hospitalization. Results: The study cohort included 4814 HCWs with COVID-19. Overall hospitalizations were 119 (2%), and there were six deaths (0.12%). Predictors of hospitalization include several co-morbidities and symptoms. A total of 1835 HCWs monitored before vaccine or monoclonal antibody availability were compared with data on U.S. HCWs in a similar time period. The monitored HCWs had a lower rate of co-morbidities (19% versus 44%, P < 0.001), a lower hospitalization rate (3% versus 8% P < 0.001) and case-fatality rate (0.11% versus 0.95% P < 0.001). Conclusions: This monitoring strategy for COVID-19 may be feasible for HBOH systems to implement and improve access to care, but more data are needed to determine if it improves outcomes.


  • Open Access

    Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems

    by Andrew H. Talal, Arpan Dharia, Shashi N. Kapadia, Gia L. Tyson, Susan Mba Birch, Judy Zerzan-Thul, Donna Sullivan, Elizabeth Msn Britton, Elaine Wethington, Christopher J. Md Gonzalez, et al.

    The US government has established a national goal of hepatitis C virus (HCV) elimination by 2030. To date, most HCV elimination planning and activity have been at the state level. Fifteen states presently have publicly available HCV elimination plans. In 2019, Louisiana and Washington were the first states to initiate 5-year funded HCV elimination programs. These states differ on motivation for pursuing HCV elimination and ranking on several indicators. Simultaneously, however, they have emphasized several similar elimination components including HCV screening promotion through public awareness, screening expansion, surveillance enhancement (including electronic reporting and task force development), and harm reduction. The 13 other states with published elimination plans have proposed the majority of the elements identified by Louisiana and Washington, but several have notable gaps. Louisiana's and Washington's comprehensive plans, funding approaches, and programs provide a useful framework that can move states and the nation toward HCV elimination.


  • Open Access

    Treatment and prevention of viral hepatitis in pregnancy

    by Jodie Dionne-Odom, Gabriella D. Cozzi, Ricardo A. Franco, Basile Njei, Alan T.N. Tita


  • Open Access

    Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population

    by Arun Rajasekaran, Ricardo A. Franco, Edgar T. Overton, Brendan M. McGuire, Graham C. Towns, Jayme E. Locke, Deirdre L. Sawinski, Emmy K. Bell


  • Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness

    by Anthony B Lee, Sandra Karumberia, Ashley Gilmore, Ebony Williams, Nichole Bruner, Edgar Turner Overton, Michael S Saag, Ricardo A Franco

    Background: The effectiveness of hepatitis C testing and linkage-to-care (LTC) is poorly characterized in low-resource jurisdictions facing gaps in harm reduction, including illegality of syringe exchange services. Effectiveness of a community-based test/LTC program was evaluated in Alabama.Methods: In 2016–2018, shelters, drug treatment centers (DTCs), AIDS organizations, and Federally Qualified Health Centers (FQHCs) engaged in screening/LTC. A coordinator navigated individuals to confirm viremia and link to substance use treatment or primary care with hepatitis C prescribers.Results: Point-of-care (POC) tested 4293 individuals (10% [427] antibody-positive, 71% [299/419] RNA performed, 80% [241/299] viremia confirmed) and 93% linked to care (225/241). Electronic medical record (EMR)-based reflex strategy screened 4654 (15% [679] antibody positive, 99% [670/679] RNA performed, 64% [433/679] viremia confirmed) and 85% linked to care (368/433). We observed higher odds of RNA confirmation in EMR-based reflex versus POC (OR, 2.07; P < .0001) and higher odds of LTC in EMR-based reflex versus POC (OR, 1.51; P < .0001). Overall, 53% individuals tested were nonbaby boomers.Conclusions: In Alabama, screening at high-risk settings identified significant hepatitis C burden and reflex testing outperformed point-of-care linkage indicators. Colocating testing in DTCs and treatment in FQHCs provided key LTC venues to at-risk younger groups.


  • Open Access

    Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality

    by Michael R Goetsch, Ashutosh Tamhane, Edgar T Overton, Graham C Towns, Ricardo A Franco

    Background: Direct-acting antiviral (DAA) therapy among hepatitis C virus (HCV)-infected kidney transplant recipients is associated with short-term improvement in protein/creatinine (P/C) ratios, but how HCV cure affects long-term graft outcomes remains unknown. Methods: This is a retrospective follow-up study of 59 HCV-infected patients who underwent kidney transplant at the University of Alabama at Birmingham between 2007-2015 who were followed until the end of 2017. We examined the association of DAA-induced HCV cure with graft failure or death by survival analyses (Kaplan-Meier, Cox regression). Redsults: Mean age was 55 years, 73% were African American, and 68% were male. Median baseline creatinine was 1.4 mg/dL, P/C ratio was 0.5, and estimated glomerular filtration rate (eGFR) was 59 mL/min. Of those who received DAA, 24 (83%) achieved cure. The remaining 5 DAA patients (17%) did not have documented evidence of sustained virologic response (SVR). Overall, 19 (32%) patients experienced graft failure or death; with lower incidence in treated patients than untreated (4 vs 15 events; 2.6 vs 10.3 per 100 person-years [cHR 0.19, 95% CI: 0.06–0.66]). When adjusted for age, sex, race, and proteinuria, the association remained strong and invariant across time-varying (aHR 0.30, 95% CI: 0.08–1.10), time-averaged (aHR 0.28, 95% CI: 0.07–1.07), and time-varying-cumulative (aHR 0.32, 95% CI: 0.08–1.21) proteinuria metrics. Conclusions: DAAs therapy was associated with improved graft survival and reduced mortality. While not statistically significant, the association was strong, and these single-center findings warrant larger studies to demonstrate the benefits of HCV treatment in this population.


  • Open Access

    Direct-acting antivirals and chronic hepatitis C: towards elimination

    by Ricardo A. Franco, James W. Galbraith, Edgar T. Overton, Michael S. Saag

    Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.